These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27718480)

  • 1. Can non-cholesterol sterols and lipoprotein subclasses distribution predict different patterns of cholesterol metabolism and statin therapy response?
    Gojkovic T; Vladimirov S; Spasojevic-Kalimanovska V; Zeljkovic A; Vekic J; Kalimanovska-Ostric D; Djuricic I; Sobajic S; Jelic-Ivanovic Z
    Clin Chem Lab Med; 2017 Mar; 55(3):447-457. PubMed ID: 27718480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of eicosapentaenoic acid may alter lipoprotein particle heterogeneity in statin-treated patients with stable coronary artery disease: A pilot 6-month randomized study.
    Tani S; Yagi T; Matsuo R; Kawauchi K; Atsumi W; Matsumoto N; Okumura Y
    J Cardiol; 2020 Nov; 76(5):487-498. PubMed ID: 32636128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Add-on" effect of phytosterols-enriched fermented milk on lipids and markers of cholesterol metabolism in statin-treated elderly patients.
    Andrade I; Santos L; Ramos F
    Steroids; 2015 Jul; 99(Pt B):293-8. PubMed ID: 25796548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gas chromatography analysis of serum cholesterol synthesis and absorption markers used to predict the efficacy of simvastatin in patients with coronary heart disease.
    Wu WF; Wang QH; Zhang T; Mi SH; Liu Y; Wang LY
    Clin Biochem; 2013 Aug; 46(12):993-998. PubMed ID: 23598259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic signatures of cholesterol biosynthesis and absorption in patients with coronary artery disease.
    Kwon GE; Hyun MH; Byun DJ; Paeng KJ; Seo HS; Choi MH
    J Steroid Biochem Mol Biol; 2021 Sep; 212():105940. PubMed ID: 34119628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis.
    Drexel H; Aczel S; Marte T; Vonbank A; Saely CH
    Atherosclerosis; 2010 Feb; 208(2):484-9. PubMed ID: 19748621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicability of non-cholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men.
    Nissinen MJ; Miettinen TE; Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):308-16. PubMed ID: 19695854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
    Shishehbor MH; Aviles RJ; Brennan ML; Fu X; Goormastic M; Pearce GL; Gokce N; Keaney JF; Penn MS; Sprecher DL; Vita JA; Hazen SL
    JAMA; 2003 Apr; 289(13):1675-80. PubMed ID: 12672736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes.
    Simonen PP; Gylling H; Miettinen TA
    Atherosclerosis; 2007 Sep; 194(1):222-9. PubMed ID: 16963050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures.
    Chu AY; Giulianini F; Barratt BJ; Ding B; Nyberg F; Mora S; Ridker PM; Chasman DI
    Circ Cardiovasc Genet; 2015 Oct; 8(5):688-95. PubMed ID: 26273092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease.
    Gylling H; Miettinen TA
    Atherosclerosis; 1996 Oct; 126(2):325-32. PubMed ID: 8902158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.